MGTX extension study longitudinally favors early thymectomy in non-thymomatous young-adult patients with AChR antibody-positive myasthenia gravis

Affiliations

¹ Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
² Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan.
³ Medical Engineering Course, Department of Engineering, Faculty of Engineering, Nagasaki Institute of Applied Science, Nagasaki, Japan.
⁴ Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.

Editorial

Tetsuya Akaishi et al. Ann Transl Med. 2019 Sep.

. 2019 Sep;7(Suppl 6):S208.

doi: 10.21037/atm.2019.06.65.

¹ Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
² Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan.
³ Medical Engineering Course, Department of Engineering, Faculty of Engineering, Nagasaki Institute of Applied Science, Nagasaki, Japan.
⁴ Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.

No abstract available

Conflict of interest statement

Conflicts of interest: The authors have no conflicts of interest to declare.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.
Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group. Wolfe GI, et al. Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25. Lancet Neurol. 2019. PMID: 30692052 Free PMC article. Clinical Trial.

1. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-8. 10.1038/85520 - DOI - PubMed
1. Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015;14:1023-36. 10.1016/S1474-4422(15)00145-3 - DOI - PubMed
1. Akaishi T, Yamaguchi T, Suzuki Y, et al. Insights into the classification of myasthenia gravis. PLoS One 2014;9:e106757. 10.1371/journal.pone.0106757 - DOI - PMC - PubMed
1. Utsugisawa K, Nagane Y. Thymic abnormalities in patients with myasthenia gravis. Brain Nerve 2011;63:685-94. - PubMed
1. Sommer N, Harcourt GC, Willcox N, et al. Acetylcholine receptor-reactive T lymphocytes from healthy subjects and myasthenia gravis patients. Neurology 1991;41:1270-6. 10.1212/WNL.41.8.1270 - DOI - PubMed